Immuno-Oncology pioneer ImmVue Therapeutics to adopt Enki™ Lead Generator to discover first-in-class cancer drugs.
Vancouver, BC – September 25, 2024 – Variational AI, developer of the Enki™ generative artificial intelligence (AI) platform for drug discovery, today announced a collaboration with ImmVue Therapeutics Inc. “We are excited to announce ImmVue as our newest Enki™ Platform customer.” said Handol Kim, CEO, Variational AI. “ImmVue’s industry-leading science has informed unique biological insights into important therapeutic targets in the fight against cancer.”
Under the collaboration, Variational AI will deliver novel and selective lead compounds to ImmVue discovered by the Enki™ Platform Lead Generator based on a pre-clinical target product profile (TPP) defined by ImmVue’s scientific team. ImmVue will pay an upfront fee and milestone based on success and have the right to own the compounds on an exclusive basis moving forward.
“We were impressed by the experimentally-validated results of Variational AI’s Enki™ Platform to efficiently generate novel leads with unmatched potency and selectivity against a range of targets of high interest in immuno-oncology ” said Sandy Der, PhD, Co-Founder & COO. “Compared to traditional chemistry approaches, Variational AI’s offering and business model are extremely compelling to biology-first companies such as ImmVue.”
“The ImmVue team has a deep and extensive understanding of the disease biology and immunology that complements and can take advantages of Variational AI’s generative chemistry capabilities,” added Kim.
About Variational AI
Variational AI has developed Enki™, the first commercially available foundation model for small molecules to enable biopharmaceutical companies to discover novel, potent, safe, and synthesizable lead compounds for a small fraction of the time and cost versus traditional chemistry approaches. To learn more, visit: www.variational.ai.
About ImmVue Therapeutics
ImmVue’s goal is develop innovative medicines that utilize novel mechanisms to revitalize the immune system of cancer patients. The foundation of ImmVue’s approach originated from the discovery of tunable lymphocyte activation to restore patients’ immune functions to eradicate cancer cells. Further information may be found at www.immvue.com.